trending Market Intelligence /marketintelligence/en/news-insights/trending/x48g7kzu6pnikwr2lcnwmw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers CEO's compensation rises to $18.7M in 2017

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Bristol-Myers CEO's compensation rises to $18.7M in 2017

Bristol-Myers Squibb Co. paid CEO Giovanni Caforio about $18.7 million in total remuneration in 2017, up from about $16.9 million in 2016.

Caforio received almost $1.6 million in base salary and received compensation of almost $3.9 million from ?non-equity incentive plan, or incentive awards, the company stated in an SEC filing.

That compares to about $1.5 million in base salary and almost $3.0 million in compensation from the non-equity incentive plan in 2016.

The New York-based pharmaceutical's CEO, who is also the company's board chairman, received $12.7 million from stock awards in comparison to $11.8 million in the year-ago period.

Caforio's market, or payout, value of unearned shares from outstanding equity awards at the end of fiscal 2017 stands at $7.4 million.

The ratio of Caforio's annual total compensation compared to Bristol-Myers' median employee's total annual compensation for fiscal year 2017 is 169 to 1, or about $18.7 million compared to $110,280, respectively.